Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B.

A Lemke1, A F Kiderlen, O Kayser

  • 1Institute of Pharmacy, Pharmaceutical Technology, Biotechnology, and Quality Management, Freie Universität Berlin, Berlin 12169, Germany.

Applied Microbiology and Biotechnology
|April 12, 2005
PubMed
Summary

Amphotericin B is an effective antifungal drug, but its kidney toxicity limits use. New formulations aim to reduce side effects, improving safety for patients with invasive fungal infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prostate gland - what would urologists like to know from radiologists?]

Der Radiologe·2017
Same author

First Draft Genome Sequence of Balamuthia mandrillaris, the Causative Agent of Amoebic Encephalitis.

Genome announcements·2015
Same author

Extracellular Vesicles from MSC Modulate the Immune Response to Renal Allografts in a MHC Disparate Rat Model.

Stem cells international·2015
Same author

Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice.

Mucosal immunology·2015
Same author

Reproductive issues in adults with cystic fibrosis: Implications for genetic counseling.

Journal of genetic counseling·2013
Same author

[Phytobezoar in the common hepatic duct - rare cause of obstructive jaundice following pancreatoduodenectomy: case report and review of the literature].

Zeitschrift fur Gastroenterologie·2012

Area of Science:

  • Pharmacology
  • Mycology
  • Drug Development

Background:

  • Invasive fungal infections pose significant risks to immunocompromised patients, including those with AIDS, transplant recipients, and cancer patients undergoing chemotherapy.
  • Amphotericin B is a highly effective antifungal medication, but its clinical utility is constrained by dose-dependent nephrotoxicity.
  • Development of novel pharmaceutical formulations is crucial to mitigate Amphotericin B's adverse effects and enhance patient safety.

Purpose of the Study:

  • To review the molecular genetics, pharmacology, toxicology, and clinical data of Amphotericin B.
  • To discuss the advancements and clinical relevance of innovative Amphotericin B formulations.
  • To provide a comprehensive overview of Amphotericin B and its improved delivery systems.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of pharmacological and toxicological profiles of Amphotericin B and its formulations.
  • Synthesis of information on molecular genetics, clinical efficacy, and safety.

Main Results:

  • Amphotericin B remains a cornerstone antifungal agent despite its toxicity.
  • Numerous novel formulations have been developed since the 1980s, with many achieving market approval.
  • These new formulations demonstrate reduced nephrotoxicity compared to the conventional form.

Conclusions:

  • Innovative Amphotericin B formulations offer an improved safety profile, particularly regarding kidney toxicity.
  • These advancements expand therapeutic options for managing invasive fungal infections in vulnerable patient populations.
  • Further research into the molecular and clinical aspects of these formulations continues to refine antifungal therapy.

Related Experiment Videos